Although studies have shown that small molecule inhibitors targeting IDH1-R132H have been effective in impairing tumor progression as monotherapy in pre-clinical models (317), in phase I clinical trials they have not been effective as monotherapies (NCT02381886). Here, IDH1 is linked to neoplasm.